Reynders McVeigh Capital Management LLC Has $13.95 Million Position in Novo Nordisk A/S $NVO

Key Points

• Reynders McVeigh Capital Management trimmed its stake in Novo Nordisk by 19.9% to 274,101 shares, leaving a position valued at about $13.95 million.
• Financial beat: Novo reported Q1 EPS of $1.01 versus $0.90 expected and revenue of $12.43 billion, with a net margin of 33.03% and return on equity of 68.91%.
• Product and competitive catalysts: Novo will start shipping the oral Ozempic pill in the U.S. on May 4 and FDA moves to limit compounding could help protect branded pricing, but growing generic semaglutide approvals and stronger competition from Eli Lilly create significant pricing and margin risk.

Reynders McVeigh Capital Management LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 19.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 274,101 shares of the company's stock after selling 68,033 shares during the period. Reynders McVeigh Capital Management LLC's holdings in Novo Nordisk A/S were worth $13,946,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in NVO. True Wealth Design LLC boosted its position in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company's stock valued at $25,000 after buying an additional 300 shares in the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S in the third quarter valued at about $25,000. WealthCollab LLC boosted its position in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after buying an additional 260 shares in the last quarter. American National Bank & Trust acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $28,000. Finally, Maseco LLP acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.1%

Shares of NYSE NVO opened at $43.84 on Monday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a market cap of $195.76 billion, a PE ratio of 12.64, a P/E/G ratio of 10.42 and a beta of 0.77. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average of $38.50 and a two-hundred day moving average of $47.19.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.34 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S's payout ratio is currently 50.43%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. BMO Capital Markets restated a "market perform" rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. TD Cowen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. CICC Research began coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an "outperform" rating and a $73.50 price target on the stock. Finally, Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a "peer perform" rating for the company. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA moves to restrict mass compounding of GLP‑1 active ingredients, which would make it harder for copycat/compounded alternatives to scale and should help protect branded pricing and volumes. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo will start shipping its oral Ozempic (semaglutide) tablets in the U.S. on May 4, expanding its addressable market beyond injectables and helping defend diabetes sales as pricing pressure mounts. Ozempic pill available in US
• Positive Sentiment: Distribution/access wins (WeightWatchers Med+ and GoodRx adding the Ozempic pill) should support uptake and patient access for the oral launch. WeightWatchers expands access to Ozempic pill
• Neutral Sentiment: Analysts’ consensus still shows material upside vs. the current price (average target ~$65.56) and small EPS estimate tweaks from Erste Group — supportive context but not immediate drivers. Analyst price targets
• Negative Sentiment: Canada approved a second generic semaglutide (Apotex), signaling increasing global generic competition that could undercut Novo’s pricing and margins in core markets over time. Canada approves second generic version of Ozempic
• Negative Sentiment: Eli Lilly’s Q1 beat, raised guidance and approval/rollout of Foundayo (an easier-to-take oral GLP‑1) widen competitive pressure on Novo’s weight‑loss franchise and could lead to share loss. Lilly's Double-Beat Widens the GLP-1 Gap
• Negative Sentiment: Ongoing concerns around pricing pressure and margin compression in the GLP‑1 market could make NVO’s recent rebound vulnerable if generics and convenience-focused rivals keep gaining traction. Pricing pressure and falling margins analysis

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.